Devroe Eric 4
4 · Acrivon Therapeutics, Inc. · Filed Jun 6, 2023
Insider Transaction Report
Form 4
Devroe Eric
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2023-06-05$1.04/sh+9,225$9,594→ 62,883 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-05−9,225→ 96,615 totalExercise: $1.04Exp: 2031-01-13→ Common Stock (9,225 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.